KIN - Kindred Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
13.75
+0.23 (+1.66%)
As of 11:51AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close13.52
Open13.60
Bid13.70 x 2200
Ask13.80 x 900
Day's Range13.60 - 13.80
52 Week Range6.80 - 15.75
Volume33,753
Avg. Volume204,965
Market Cap464.746M
Beta-0.07
PE Ratio (TTM)N/A
EPS (TTM)-1.39
Earnings DateFeb 27, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.82
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

    SAN FRANCISCO , Sept. 17, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • PR Newswire26 days ago

    Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

    SAN FRANCISCO , Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in ...

  • Thomson Reuters StreetEvents29 days ago

    Edited Transcript of KIN earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Kindred Biosciences Inc Earnings Call

  • PR Newswirelast month

    Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

    SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York at the New York Marriott East Side. Denise Bevers, Co-Founder and Chief Operating Officer, will be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.

  • PR Newswire2 months ago

    Kindred Biosciences Announces Second Quarter 2018 Financial Results

    SAN FRANCISCO , Aug. 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial ...

  • PR Newswire2 months ago

    Kindred Biosciences to Announce Second Quarter 2018 Financial Results

    Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, August 9, 2018 SAN FRANCISCO , July 16, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

  • PR Newswire3 months ago

    Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

    SAN FRANCISCO, July 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States. Mirataz is the first and only transdermal medication for the management of weight loss in cats approved by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine. Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats.

  • PR Newswire3 months ago

    Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

    SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced the underwriters have exercised in full their option to purchase an additional 694,736 shares of KindredBio's common stock at $9.50 per share, less underwriting discounts and commissions. KindredBio also announced that it has closed its public offering of 5,326,314 shares of common stock at a public offering price of $9.50 per share, which included the sale of the shares pursuant to the option to purchase additional shares, for a total offering amount of approximately $50.6 million before deducting underwriting discounts and commissions and offering expenses payable by KindredBio. Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.  B. Riley FBR acted as co-manager.  A.G.P. / Alliance Global Partners, H.C. Wainwright & Co., Ladenburg Thalmann, and Lake Street Capital Markets LLC provided financial advisory services.

  • PR Newswire3 months ago

    Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

    SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering program (the "ATM Facility") with B. Riley FBR, Inc. and Oppenheimer & Co. Inc. as sales agents. "With the recent successful offering, KindredBio is now well capitalized and we do not anticipate requiring additional funding to achieve our current corporate and development objectives," stated Richard Chin, CEO of KindredBio.

  • PR Newswire3 months ago

    Kindred Biosciences Announces Pricing of Public Offering

    SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,631,578 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $44 million before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 694,736 shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering and B. Riley FBR is acting as the co-manager.  A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.

  • PR Newswire3 months ago

    Kindred Biosciences Announces Proposed Public Offering of Common Stock

    SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering and B. Riley is acting as the co-manager. KindredBio intends to use the net proceeds from the offering, if completed, for the expansion of its commercial infrastructure in anticipation of future product approvals and launches, for expansion of its manufacturing capacity, the development of its therapeutic candidates, and for other general corporate and working capital purposes.

  • Who Owns Most Of Prima Park SA. (WSE:KIN)?
    Simply Wall St.4 months ago

    Who Owns Most Of Prima Park SA. (WSE:KIN)?

    In this article, I will take a quick look at Prima Park SA.’s (WSE:KIN) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structureRead More...

  • PR Newswire4 months ago

    KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses

    SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses. This study was a randomized, single-blind, placebo-controlled, dose-ranging study that enrolled 53 horses (40 horses in three KIND-014 groups with different doses and dosing schedules, 13 horses in the placebo group). The objective was to determine the effective dose of KIND-014 for the treatment of gastric ulcers in horses.

  • PR Newswire4 months ago

    Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference

    SAN FRANCISCO , May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • PR Newswire4 months ago

    Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference

    SAN FRANCISCO , May 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Kindred Biosciences Inc Earnings Call

  • ACCESSWIRE5 months ago

    Blog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz

    LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want access to our free research report on Kindred Biosciences, Inc. (NASDAQ: KIN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KIN as the Company's latest news hit the wire. On May 7, 2018, the Company, which is a biopharmaceutical organization focused on saving and improving the lives of pets, declared that the US Food and Drug Administration (FDA)'s Center for Veterinary Medicine has approved mirtazapine transdermal ointment, or Mirataz, for the management of weight loss in cats.

  • PR Newswire5 months ago

    Kindred Biosciences Announces First Quarter 2018 Financial Results

    "We are excited about the recent approval of our first product, Mirataz™, for the management of weight loss in cats. This first-in-class medicine, which is the only FDA-approved treatment for this indication, and the first transdermal product ever approved for cats by FDA, will help millions of cats with a serious and potentially fatal unmet medical need," stated Richard Chin, CEO of KindredBio.

  • Is Prima Park SA. (WSE:KIN) A Financially Sound Company?
    Simply Wall St.5 months ago

    Is Prima Park SA. (WSE:KIN) A Financially Sound Company?

    While small-cap stocks, such as Prima Park SA. (WSE:KIN) with its market cap of ZŁ4.52M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • This Peninsula company's new drug is the cat's meow — the FDA says so
    American City Business Journals5 months ago

    This Peninsula company's new drug is the cat's meow — the FDA says so

    The first drug ointment approved by the FDA started as an antidepressant pill for humans.

  • PR Newswire5 months ago

    Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats

    "We are pleased to announce the FDA approval of Mirataz for cats experiencing unintended weight loss, a serious medical and potentially fatal condition," said Richard Chin, M.D., President and Chief Executive Officer of KindredBio. "Based on our market research, we estimate that veterinarians in the U.S. see as many as 9 million cats each year with unintended weight loss due to various underlying conditions.

  • PR Newswire5 months ago

    Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors

    SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the appointment of Ernest Mario, Ph.D. and Joseph McCracken, D.V.M. to its Board of Directors. Dr. Mario brings to KindredBio 50 years of experience in the pharmaceutical industry.